Peer-reviewed veterinary case report
Dog lymphoma chemo with doxorubicin or mitoxantrone side effects
By Wang, Shang-Lin et al.Ā·Published in The Canadian veterinary journal = La revue veterinaire canadienneĀ·2016Ā·National Taiwan University Veterinary Hospital, ChinaĀ·View original on PubMed ā
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research ā every detail traces back to the citation above. How we work ā
Original publication title: Comparison of efficacy and toxicity of doxorubicin and mitoxantrone in combination chemotherapy for canine lymphoma.
- Species:
- dog
Plain-English summary
Forty-four dogs with multicentric lymphoma (a type of cancer affecting the lymph nodes) were treated with two different chemotherapy combinations. One group received a treatment called CHOP, while the other group received CMOP. Both treatments had similar effectiveness in terms of how long the dogs lived without the cancer worsening, but the CMOP group experienced fewer side effects like loss of appetite and diarrhea. This suggests that CMOP could be a good alternative for treating lymphoma in dogs, offering similar results with less discomfort.
People also search for: dog lymphoma treatment options Ā· canine chemotherapy side effects Ā· lymphoma in dogs survival rate
Abstract
Forty-four dogs with multicentric lymphoma were treated using a cyclophosphamide, doxorubicin, vincristine, and prednisolone (CHOP) induction protocol or treated using a cyclophosphamide, mitoxantrone, vincristine, and prednisolone (CMOP) induction protocol. There was no statistical difference in signalment and the presence of historical negative prognostic factors between the groups. The median progression-free survival (PFS) in the CHOP and CMOP groups were 222 d and 162 d, respectively (P = 0.75). The median survival time (MST) of dogs in CHOP and CMOP groups were 318 d and 242 d, respectively (P = 0.63). Anorexia and diarrhea episodes were significantly higher in the CHOP group than in the CMOP group (P = 0.02 and P = 0.01, respectively). These results suggest that the CMOP protocol provides similar PFS, MST and causes fewer side effects compared to the CHOP protocol. Therefore, the CMOP protocol may be another treatment choice for canine multicentric lymphoma.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases āOriginal publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/26933263/